Comparing adult height gain and menarcheal age between girls with central precocious puberty treated with gonadotropin-releasing hormone agonist alone and those treated with combined growth hormone therapy
10.6065/apem.2019.24.2.116
- Author:
Min Sub KIM
1
;
Hyo Jung KOH
;
Gwang Yeon LEE
;
Dong Hee KANG
;
Se Young KIM
Author Information
1. Department of Pediatrics, Bundang Jesaeng General Hospital, Daejin Medical Center, Seongnam, Korea. odajulia@dmc.or.kr
- Publication Type:Original Article
- Keywords:
Puberty;
Precocious;
Gonadotropin-releasing hormone;
Growth hormone;
Body Height
- MeSH:
Adolescent;
Adult;
Body Height;
Female;
Gonadotropin-Releasing Hormone;
Growth Hormone;
Humans;
Medical Records;
Puberty;
Puberty, Precocious;
Retrospective Studies
- From:Annals of Pediatric Endocrinology & Metabolism
2019;24(2):116-123
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study aimed to investigate the outcomes of gonadotropin-releasing hormone agonist (GnRHa) therapy with or without growth hormone (GH) therapy for girls with idiopathic central precocious puberty (CPP). METHODS: The medical records of 166 girls diagnosed with CPP from 2002 to 2017 were retrospectively reviewed. All included patients were treated with GnRHa for ≥36 months. Changes in height standard deviation score (SDS) for bone age, chronological age (CA), and predicted adult height (PAH) were assessed for the first three years of treatment. The final height gain SDS was calculated as the difference between the initial PAH SDS and adult height (AH) SDS; these were then compared between the GnRHa group (group A, n=135) and the combined GnRHa/GH group (group B, n=31).
